The estimated Net Worth of Amy L. Burroughs is at least $197 Tausend dollars as of 16 August 2021. Amy Burroughs owns over 44,950 units of DiaMedica Therapeutics stock worth over $196,881 and over the last 3 years Amy sold DMAC stock worth over $0.
Amy has made over 1 trades of the DiaMedica Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Amy bought 44,950 units of DMAC stock worth $141,593 on 16 August 2021.
The largest trade Amy's ever made was buying 44,950 units of DiaMedica Therapeutics stock on 16 August 2021 worth over $141,593. On average, Amy trades about 8,990 units every 0 days since 2021. As of 16 August 2021 Amy still owns at least 44,950 units of DiaMedica Therapeutics stock.
You can see the complete history of Amy Burroughs stock trades at the bottom of the page.
Amy's mailing address filed with the SEC is 301 CARLSON PARKWAY, SUITE 210, , MINNEAPOLIS, MN, 55305.
Over the last 6 years, insiders at DiaMedica Therapeutics have traded over $0 worth of DiaMedica Therapeutics stock and bought 7,996,631 units worth $17,281,380 . The most active insiders traders include Koch Thomas Tom Enterprise ..., Jantrill Ab Stahlberg und David J. Wambeke. On average, DiaMedica Therapeutics executives and independent directors trade stock every 48 days with the average trade being worth of $833,934. The most recent stock trade was executed by Koch Thomas Tom Enterprise ... on 28 June 2024, trading 1,200,000 units of DMAC stock currently worth $3,000,000.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics executives and other stock owners filed with the SEC include: